Valerio G, Di Maio S, Salerno M, Argenziano A, Badolato R, Tenore A
Departments of Pediatrics, University of Udine, School of Medicine, Italy.
Horm Res. 1997;47(2):62-6. doi: 10.1159/000185433.
In order to evaluate the effect of growth hormone (GH) on erythropoiesis, red blood cell (RBC) indices (hemoglobin, Hb; hematocrit, Ht; RBC count, and mean corpuscular volume, MCV) of 19 GH-deficient children (12 with isolated GH deficiency and 7 with multiple pituitary hormone deficiencies) between 2 months and 15 years of age were compared to those of 57 sex- and age-matched short normal controls before starting treatment with recombinant human GH (rhGH). The RBC indices were expressed as standard deviation score (SDS). Moreover, the RBC indices in the GH-deficient group were analyzed after the first 3 and 6 months of GH treatment and compared to those of 9 Ullrich-Turner syndrome (UTS) patients with GH therapy. Both patients with isolated and those with multiple pituitary hormone deficiencies presented significantly lower values of Hb-SDS (-1.6 +/- 1.0 and -2.0 +/- 1.4, respectively; p = 0.004), Ht-SDS (-1.55 +/- 0.9 and -2.5 +/- 2.1, respectively; p = 0.001) and RBC-SDS (-0.6 +/- 1.6 and -1.2 +/- 0.9, respectively; p = 0.002) when compared to controls (Hb-SDS: -0.6 +/- 1.4; Ht-SDS: -0.1 +/- 1.9; RBC-SDS: 0.17 +/- 1), in the presence of comparable MCV-SDS values. In contrast, RBC indices did not differ between patients with isolated and those with multiple pituitary hormone deficiencies. When the variations of RBC indices were analyzed after 3 and 6 months of rhGH therapy in the 19 GH-deficient children, an increase in the Hb-SDS (p = 0.01), Ht-SDS (p = 0.03) and RBC-SDS was observed, indicating an early stimulatory effect on RBC proliferation in these patients. However, an analysis of the RBC indices in the group of UTS patients did not reveal any significant change after both 3 and 6 months of therapy with rhGh. The increase in Hb, Ht, and RBC count observed during GH treatment confirms the in vivo erythropoietic growth-promoting effects of GH. However, this effect seems to be related only to conditions of GH deficiency. When GH deficiency is associated with multiple pituitary hormone deficiencies there are pathological influences on erythropoiesis which are not corrected until Gh treatment is started, indicating a 'permissive' role of GH in the hematopoietic system.
为了评估生长激素（GH）对红细胞生成的影响，将19名2个月至15岁的生长激素缺乏儿童（12名单纯生长激素缺乏，7名多种垂体激素缺乏）在开始重组人生长激素（rhGH）治疗前的红细胞（RBC）指标（血红蛋白，Hb；血细胞比容，Ht；红细胞计数和平均红细胞体积，MCV）与57名性别和年龄匹配的身材矮小正常对照者的指标进行比较。红细胞指标以标准差评分（SDS）表示。此外，对生长激素缺乏组在生长激素治疗的前3个月和6个月后的红细胞指标进行分析，并与9名接受生长激素治疗的乌尔里希-特纳综合征（UTS）患者的指标进行比较。单纯生长激素缺乏患者和多种垂体激素缺乏患者的Hb-SDS值（分别为-1.6±1.0和-2.0±1.4；p = 0.004）、Ht-SDS值（分别为-1.55±0.9和-2.5±2.1；p = 0.001）和RBC-SDS值（分别为-0.6±1.6和-1.2±0.9；p = 0.002）与对照组相比均显著降低（Hb-SDS：-0.6±1.4；Ht-SDS：-0.1±1.9；RBC-SDS：0.
